• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    5/23/24 8:06:48 AM ET
    $AEON
    $BCYC
    $CALT
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEON alert in real time by email

    Gainers

    • OneMedNet (NASDAQ:ONMD) shares moved upwards by 103.2% to $1.0 during Thursday's pre-market session. The company's market cap stands at $23.7 million.
    • iSpecimen (NASDAQ:ISPC) stock moved upwards by 30.67% to $0.41. The market value of their outstanding shares is at $4.1 million.
    • P3 Health Partners (NASDAQ:PIII) stock increased by 25.51% to $0.63. The company's market cap stands at $75.3 million.
    • Bicycle Therapeutics (NASDAQ:BCYC) stock increased by 12.04% to $24.0. The company's market cap stands at $913.7 million.
    • Calliditas Therapeutics (NASDAQ:CALT) stock moved upwards by 11.42% to $24.19. The market value of their outstanding shares is at $649.1 million. The company's, Q1 earnings came out today.
    • AEON Biopharma (AMEX:AEON) shares rose 11.41% to $2.22. The market value of their outstanding shares is at $86.7 million.

    Losers

    • Ensysce Biosciences (NASDAQ:ENSC) stock decreased by 21.5% to $0.5 during Thursday's pre-market session. The market value of their outstanding shares is at $3.7 million.
    • Cytokinetics (NASDAQ:CYTK) stock fell 14.58% to $50.6. The market value of their outstanding shares is at $5.3 billion.
    • DermTech (NASDAQ:DMTK) shares fell 12.15% to $0.37. The company's market cap stands at $12.9 million.
    • SILO Pharma (NASDAQ:SILO) shares declined by 12.0% to $2.02. The company's market cap stands at $5.6 million.
    • Tango Therapeutics (NASDAQ:TNGX) shares fell 11.91% to $6.51. The market value of their outstanding shares is at $695.5 million.
    • Vicarious Surgical (NYSE:RBOT) shares declined by 11.48% to $0.37. The company's market cap stands at $65.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AEON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEON
    $BCYC
    $CALT
    $CYTK

    CompanyDatePrice TargetRatingAnalyst
    Tango Therapeutics Inc.
    $TNGX
    2/23/2026$19.00Outperform
    Mizuho
    Cytokinetics Incorporated
    $CYTK
    1/28/2026$87.00Overweight
    Barclays
    Cytokinetics Incorporated
    $CYTK
    12/18/2025$95.00Neutral → Buy
    Goldman
    Bicycle Therapeutics plc
    $BCYC
    11/24/2025$19.00Hold
    Truist
    Tango Therapeutics Inc.
    $TNGX
    11/18/2025Peer Perform
    Wolfe Research
    Bicycle Therapeutics plc
    $BCYC
    10/31/2025$11.00Outperform → Sector Perform
    RBC Capital Mkts
    P3 Health Partners Inc.
    $PIII
    8/28/2025$20.00Buy
    Lake Street
    Tango Therapeutics Inc.
    $TNGX
    8/19/2025$11.00Overweight
    Piper Sandler
    More analyst ratings

    $AEON
    $BCYC
    $CALT
    $CYTK
    SEC Filings

    View All

    SEC Form S-8 filed by Cytokinetics Incorporated

    S-8 - CYTOKINETICS INC (0001061983) (Filer)

    2/26/26 5:35:35 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Cytokinetics Incorporated

    10-K - CYTOKINETICS INC (0001061983) (Filer)

    2/26/26 4:01:01 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CYTOKINETICS INC (0001061983) (Filer)

    2/24/26 4:13:51 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEON
    $BCYC
    $CALT
    $CYTK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TARPEYO issued to CALLIDITAS THERAPEUTICS AB

    Submission status for CALLIDITAS THERAPEUTICS AB's drug TARPEYO (ORIG-1) with active ingredient BUDESONIDE has changed to 'Approval' on 12/15/2021. Application Category: NDA, Application Number: 215935, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/20/21 3:40:41 PM ET
    $CALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEON
    $BCYC
    $CALT
    $CYTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Weisblum Eric bought $2,075 worth of shares (5,000 units at $0.41), increasing direct ownership by 2% to 216,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    12/16/25 6:34:59 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Medical Officer Yu Jeffrey converted options into 2,307,549 shares, bought $959,586 worth of shares (2,010,479 units at $0.48) and was granted 245,000 shares, increasing direct ownership by 165% to 7,326,223 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:56:08 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Medical Officer Yu Jeffrey bought $8,929 worth of shares (9,540 units at $0.94) and was granted 230,769 shares, increasing direct ownership by 10% to 2,763,195 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:55:32 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $AEON
    $BCYC
    $CALT
    $CYTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Follow-Through Leaders: Production Ramps, AI Alliances, Balance Sheet Strength

    DENVER, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Markets reward momentum and trends may sustain when execution follows headlines. Several companies are now moving beyond announcements and into operational validation, positioning themselves for potential continued follow-through. From biomaterials scale-up to enterprise AI deployment and disciplined capital allocation, these names are building narratives that extend beyond a single news cycle. Kraig Biocraft Laboratories: From Strategy to Scale Activity has accelerated at Kraig Biocraft Laboratories (OTCQB:KBLB) following confirmation that its 2026 production plan has officially transitioned from roadmap to execution. The company has moved bio

    2/27/26 9:45:46 AM ET
    $ENSC
    $PLTR
    $RXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology

    OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry

    MINNEAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) (the "OneMedNet," the "Company," "we," "us" or "our"), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced the next phase of commercial launch with its RWD Platform powered by Palantir Foundry. Following the successful November 10, 2025, demonstration of live feeds, subscription access, and AI-driven search at major tradeshows, the Company is actively converting customer evaluations into commercial subscriptions. Early results highlight superior performance, speed and analytical depth, reinforcing OneMedNet's position for life sciences and healthcare organizations generati

    2/27/26 8:50:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OneMedNet Partners with ViuHealth to Enhance Autoimmune Dataset Scale, Accelerating Recurring Revenue from Life Sciences and AI Customers

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a strategic partnership with ViuHealth, a digital health company specializing in autoimmune disease populations. This partnership expands OneMedNet's autoimmune clinical ontology, to the OneMedNet iRWD™ platform—powered by Palantir Foundry—further increasing the scale, diversity, and longitudinal depth of its regulatory-grade Real-World Data. Under the agreement, ViuHealth will provide ongoing, longitudinal autoimmune disease data, strengthening OneMedNet's portfolio of high-value specialty datasets and supporting resea

    2/26/26 8:40:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $AEON
    $BCYC
    $CALT
    $CYTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on Tango Therapeutics with a new price target

    Mizuho initiated coverage of Tango Therapeutics with a rating of Outperform and set a new price target of $19.00

    2/23/26 8:40:01 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on Cytokinetics with a new price target

    Barclays resumed coverage of Cytokinetics with a rating of Overweight and set a new price target of $87.00

    1/28/26 7:16:37 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics upgraded by Goldman with a new price target

    Goldman upgraded Cytokinetics from Neutral to Buy and set a new price target of $95.00

    12/18/25 8:41:18 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEON
    $BCYC
    $CALT
    $CYTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Sachs Adam David sold $1,967 worth of shares (942 units at $2.09), decreasing direct ownership by 2% to 46,943 units (SEC Form 4)

    4 - Vicarious Surgical Inc. (0001812173) (Issuer)

    2/24/26 4:59:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Chief Technology Officer Khalifa Sammy sold $1,571 worth of shares (754 units at $2.08), decreasing direct ownership by 2% to 32,869 units (SEC Form 4)

    4 - Vicarious Surgical Inc. (0001812173) (Issuer)

    2/24/26 4:58:35 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    PRESIDENT & CEO Bancroft Robert E. was granted 3,000,000 shares, increasing direct ownership by 1,694% to 3,177,103 units (SEC Form 4)

    4 - AEON Biopharma, Inc. (0001837607) (Issuer)

    2/19/26 8:40:27 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEON
    $BCYC
    $CALT
    $CYTK
    Leadership Updates

    Live Leadership Updates

    View All

    Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

    "On Track with HCM" Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone's Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the launch of "On Track with HCM," demonstrating the company's long-standing commitment to the HCM community. The campaign features four-time Olympic gold medalist Sydney McLaughlin-Levrone, and her father, three-time all-American track star, Willie McLaughlin, who suffered from the non-obstructive form of hypertrophic cardiomyopathy (HCM) for more than two decades before receiving a heart trans

    1/27/26 8:00:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

    Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately – BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines today announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effective today January 8, 2026. Dr. Weber, the company's founding CEO, will become Executive Chair for 2026 and then serve as non-executive chair starting in 2027. She is succeeded by Dr. Malte Peters, a

    1/8/26 9:05:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Appoints Sung Lee to Board of Directors

    BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Mr. Sung Lee to the Board of Directors. Mr. Lee has over 20 years of experience in finance leadership in the biopharmaceutical and technology industries. "We are delighted to welcome Sung Lee to our Board of Directors," said Barbara Weber, M.D., Chief Executive Officer of Tango Therapeutics. "Sung's proven track record in corporate strategy, investor relations and finance will be instrumental as we advance our lead program, vopimetostat, into reg

    1/5/26 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEON
    $BCYC
    $CALT
    $CYTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Bicycle Therapeutics plc

    SC 13D/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

    12/17/24 6:46:27 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Tango Therapeutics Inc.

    SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

    11/20/24 4:24:26 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Ensysce Biosciences Inc.

    SC 13G - Ensysce Biosciences, Inc. (0001716947) (Subject)

    11/14/24 5:52:56 PM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEON
    $BCYC
    $CALT
    $CYTK
    Financials

    Live finance-specific insights

    View All

    Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update

    MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for MAPLE-HCM Submitted to FDA in Q1 2026 Expect to Share Topline Results from ACACIA-HCM in Q2 2026 Company Provides 2026 Financial Guidance;~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the fourth quarter and full year of 2025. The company also provided full year 2026 financial guidance. "The fourth qu

    2/24/26 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences

    BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S. financial markets. The company does not intend to hold a conference call. Additionally, Tango Therapeutics management is scheduled to participate in three upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, Boston Corporate presentation on Wednesday, March 4 at 1:10-1:40 PM ETWebcast link here Barclays 28th Annual Global Healthcare Conference, Miami Hosting 1x1 meetings on Tuesday, March 10 2026 Leerink Partners Global Healthcare Conference, Miami Fireside chat

    2/18/26 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics to Announce Fourth Quarter Results on February 24, 2026

    SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at www.cytokinetics.com or directly at the following link: Cytokinetics Q4 2025 Earnings Conference Call. An archived replay of the webcast will be available via Cytokinetics'

    2/12/26 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care